Key Insights

Highlights

Success Rate

90% trial completion (above average)

Published Results

16 trials with published results (21%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

5.2%

4 terminated out of 77 trials

Success Rate

90.5%

+4.0% vs benchmark

Late-Stage Pipeline

1%

1 trials in Phase 3/4

Results Transparency

42%

16 of 38 completed with results

Key Signals

16 with results90% success

Data Visualizations

Phase Distribution

64Total
Not Applicable (6)
Early P 1 (1)
P 1 (33)
P 2 (23)
P 4 (1)

Trial Status

Completed38
Recruiting14
Active Not Recruiting11
Withdrawn5
Terminated4
Unknown3

Trial Success Rate

90.5%

Benchmark: 86.5%

Based on 38 completed trials

Clinical Trials (77)

Showing 20 of 20 trials
NCT04616560Phase 1Suspended

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Newly Diagnosed, Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

NCT02867592Phase 2Active Not Recruiting

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

NCT03155620Phase 2Active Not Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

NCT03210714Phase 2Active Not Recruiting

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

NCT04195555Phase 2Active Not Recruiting

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

NCT04320888Phase 2Active Not Recruiting

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

NCT03213652Phase 2Active Not Recruiting

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

NCT03698994Phase 2Active Not Recruiting

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

NCT07172958Phase 1Recruiting

Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

NCT04897321Phase 1Recruiting

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

NCT00898365Completed

Study of Kidney Tumors in Younger Patients

NCT07584499Phase 1Recruiting

Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors

NCT05985161Phase 2RecruitingPrimary

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

NCT04851119Phase 1Recruiting

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

NCT04483778Phase 1Active Not Recruiting

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

NCT04968990Phase 2RecruitingPrimary

Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation

NCT03213678Phase 2Completed

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

NCT04308330Phase 1Recruiting

Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

NCT03810651Early Phase 1Recruiting

Pencil Beam Scanning in Patients With Renal Tumors

NCT03213665Phase 2Completed

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Scroll to load more

Research Network

Activity Timeline